MDxHealth (MDXH) Corporate presentation summary

Business and growth platform

• Urologic diagnostics span prostate cancer screening, biopsy follow-up and localized cancer treatment decisions; more than 500,000 patients tested.

• Acquisitions added GPS in August 2022 and ExoDx in September 2025; the expanded commercial team exceeds 80 people.

• Commercial strategy positions the portfolio as a standardized laboratory partner for urology practices, supported by Medicare coverage and an established distribution channel.

Prostate diagnostic portfolio

• ExoDx is a non-invasive urine test requiring no DRE; reported NPV is 91.3% for Gleason ≥3+4 and 97% for Gleason ≥4+3.

• Confirm mdx uses prior biopsy tissue to assess risk after a negative biopsy; reported 96% NPV for aggressive prostate cancer and inclusion in EAU and NCCN guidelines.

• GPS mdx analyzes prior biopsy tissue to predict adverse pathology, distant metastasis and prostate cancer mortality, informing surveillance and treatment intensity.

• Monitor mdx is in development as a non-invasive risk-stratification option for active-surveillance patients, with an estimated annual market of 1.5M men.

Market and growth opportunities

• U.S. prostate menu market opportunity presented at $4.8B, spanning Confirm mdx, ExoDx, GPS mdx and Monitor mdx.

• Growth levers include broader payer coverage, menu expansion, channel opportunities beyond urology and potential decentralization of testing.

• Clinical evidence includes 11 published ExoDx studies, over 55 Confirm mdx studies and over 20 GPS validation and utility studies.